On March 7, 2024, the U.S. Food and Drug Administration (FDA) announced it has approved Bruton tyrosine kinase inhibitor (BTKi), zanubrutinib (Brukinsa, BeiGene USA, Inc.) with obinutuzumab for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) after two…
Celebrating the Original ‘Chemo Diva’ Upon receiving a lymphoma diagnosis, it’s not uncommon to search for others like you who are going through a similar experience. That sense of community and support, of seeing your own story reflected to you,…
Where Are They Now? Ryan Lynch, MD Dr. Ryan Lynch is a hematologist-oncologist at Fred Hutchinson Cancer Center. When did you become interested in the study of medicine? In lymphoma specifically? I had a great opportunity while I was in…
Advancing Cures and Developing the Next Generation of Lymphoma Researchers Growing up in Spoleto, Italy, Laura Pasqualucci, MD, loved classical music. While her appreciation for music led her to attend a conservatory to study the art form, it was ultimately…
Morton Coleman, MD Innovation Fund Dr. Morton Coleman is a world-renowned and highly respected medical oncologist with nearly 60 years of experience in the field, specializing in the treatment of patients with lymphoma, multiple myeloma, and leukemia. In 2023, the…
Dear Friends of the Lymphoma Research Foundation, The Lymphoma Research Foundation (LRF) is defined by its tirelesscommitment to our mission: eradicating lymphoma and serving thosewho have been touched by this disease. With each breakthrough, we areone step closer to reaching…
Updates from the 2023 American Society of Hematology Annual Meeting The Lymphoma Research Foundation (LRF) returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 318 LRF-affiliated scientists, including past and present members of LRF’s world-leading Scientific…
ASH 2023: Increased Metabolism in High IRF4-Expressing Lymphoma Cells Limits the Availability of Glucose in the Tumor Microenvironment Cancer cells routinely reprogram cellular metabolism to improve their fitness, providing a selective advantage that supports growth and expansion. Researchers previously determined…
ASH 2023: Durable Responses Observed with Valemetostat Improved Outcomes in Second-Line Treatment of Large B-Cell Lymphoma in the Era of CAR T-Cell Therapies The treatment landscape of large B-cell lymphomas (LBCL) has changed dramatically in recent years, driven in part…
ASH 2023: Durable Responses Observed with Valemetostat Tosylate Treatment in Relapsed/Refractory Peripheral T-Cell Lymphoma Treatment options for relapsed or refractory peripheral T-cell lymphoma (PTCL) are limited, and many patients experience an aggressive disease course. In the phase 2 VALENTINE-PTCL01 study,…